AC Immune Reports Full Year 2023 Financial Results
AC Immune Announces Upcoming Presentations at AD/PD 2024 Multiple presentations at the International Conference on Alzheimer™s and Parkinson™s Diseases (AD/PD 2024)Andrea Pfeifer, Ph.D., CEO to...
AC Immune to Regain Global Rights to Crenezumab and Semorinemab Company™s strategy is focused on advancing the Phase 2 development of its three active immunotherapiesActive immunotherapy now...
Genentech is walking away from an 18-year relationship with AC Immune, handing back global rights to a pair of Alzheimer’s disease drug candidates after suffering a series of setbacks in the clinic.
AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases ABATE Phase 1b/2 AD trial of ACI-24.060 completed enrollment of cohorts 1 and 2 and...
AC Immune™s Targeted Anti-pTau Active Immunotherapy for Alzheimer™s Disease Advances into Phase 2b Trial Potentially registration-enabling Phase 2b study (ReTain) will evaluate the effect of...
AC Immune Announces Pricing of Underwritten Offering of Common Shares Lausanne, Switzerland, December 15, 2023 “ AC Immune SA (Nasdaq: ACIU) (the œCompany or œAC Immune), a clinical-stage...
AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO Outstanding scientist and entrepreneur Dr. Madiha Derouazi appointed as new CSORetiring CSO Dr....
AC Immune to Present at the Jefferies 2023 London Healthcare Conference Lausanne, Switzerland, November 7, 2023 AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering...
AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update Results from amyloid plaque reduction analysis (Abeta-PET) after 6 months of treatment with ACI-24.060 in ABATE...